| RS2520865607 |
CACNA1F
|
Health Risk |
Likely pathogenic |
X-linked cone-rod dystrophy 3, X-linked cone-rod dystrophy 3 |
| RS2520865886 |
CHM
|
Health Risk |
Likely pathogenic |
Retinal dystrophy, Retinal dystrophy |
| RS2520865940 |
CHM
|
Health Risk |
Likely pathogenic |
Choroideremia, Choroideremia |
| RS2520866043 |
CHM
|
Health Risk |
Pathogenic |
— |
| RS2520866066 |
SOX3
|
Health Risk |
Pathogenic |
X-linked intellectual disability with isolated growth hormone deficiency, X-linked intellectual disability with isolated growth hormone deficiency |
| RS2520866183 |
CHM
|
Health Risk |
Likely pathogenic |
Choroideremia, Choroideremia |
| RS2520866393 |
CHM
|
Health Risk |
Likely pathogenic |
Choroideremia, Choroideremia |
| RS2520867051 |
CHM
|
Health Risk |
Likely pathogenic |
Retinal dystrophy, Retinal dystrophy |
| RS2520867977 |
CACNA1F
|
Health Risk |
Likely pathogenic |
Congenital stationary night blindness 2A, Congenital stationary night blindness 2A |
| RS2520868157 |
CACNA1F
|
Health Risk |
Pathogenic |
— |
| RS2520869335 |
GLA
|
Health Risk |
Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520869573 |
GLA
|
Health Risk |
Conflicting classifications of pathogenicity |
Fabry disease, Fabry disease |
| RS2520871549 |
CACNA1F
|
Health Risk |
Pathogenic |
— |
| RS2520872355 |
CACNA1F
|
Health Risk |
Pathogenic |
— |
| RS2520877178 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520877438 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520884260 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520884503 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520884782 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520884993 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520885035 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Developmental and epileptic encephalopathy |
| RS2520885299 |
SMC1A
|
Health Risk |
Likely pathogenic |
— |
| RS2520886754 |
GLA
|
Health Risk |
Pathogenic/Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520887188 |
GLA
|
Health Risk |
Pathogenic/Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520887287 |
GLA
|
Health Risk |
Pathogenic |
Fabry disease, Fabry disease |
| RS2520887376 |
GLA
|
Health Risk |
Pathogenic |
Fabry disease, Fabry disease |
| RS2520887463 |
GLA
|
Health Risk |
Pathogenic |
Fabry disease, Fabry disease |
| RS2520889050 |
LARGE1
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy type B6, Muscular dystrophy-dystroglycanopathy type B6 |
| RS2520895017 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520895106 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520895194 |
GLA
|
Health Risk |
Pathogenic/Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520895216 |
GLA
|
Health Risk |
Pathogenic/Likely pathogenic |
Cardiovascular phenotype, Fabry disease |
| RS2520895308 |
IDS
|
Health Risk |
Conflicting classifications of pathogenicity |
Mucopolysaccharidosis, MPS-II |
| RS2520895663 |
IDS
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520895683 |
GLA
|
Health Risk |
Pathogenic |
Fabry disease, Fabry disease |
| RS2520895871 |
IDS
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520896006 |
IDS
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520896190 |
IDS
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520896777 |
IDS
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520896826 |
IDS
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520897240 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520897254 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520897726 |
GLA
|
Health Risk |
Conflicting classifications of pathogenicity |
Fabry disease, Fabry disease |
| RS2520897937 |
GLA
|
Health Risk |
Pathogenic |
Fabry disease, Fabry disease |
| RS2520900006 |
IDS
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2520900502 |
IDS
|
Health Risk |
Pathogenic/Likely pathogenic |
Inborn genetic diseases, Mucopolysaccharidosis |
| RS2520900702 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520900881 |
IDS
|
Health Risk |
Conflicting classifications of pathogenicity |
Mucopolysaccharidosis, MPS-II |
| RS2520900915 |
IDS
|
Health Risk |
Likely pathogenic |
Inborn genetic diseases, Mucopolysaccharidosis |
| RS2520901143 |
IDS
|
Health Risk |
Conflicting classifications of pathogenicity |
Mucopolysaccharidosis, MPS-II |
| RS2520901458 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520901887 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520901934 |
IDS
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520902533 |
IDS
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520902687 |
CACNA1F
|
Health Risk |
Pathogenic |
— |
| RS2520903522 |
CACNA1F
|
Health Risk |
Pathogenic |
— |
| RS2520904563 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520904776 |
SMC1A
|
Health Risk |
Pathogenic |
— |
| RS2520905278 |
CACNA1F
|
Health Risk |
Likely pathogenic |
— |
| RS2520906768 |
CACNA1F
|
Health Risk |
Likely pathogenic |
Cone-rod dystrophy, Cone-rod dystrophy |
| RS2520906991 |
LAMP2
|
Health Risk |
Pathogenic |
Cardiovascular phenotype, Cardiovascular phenotype |
| RS2520907960 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520908238 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520908416 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520910742 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520910813 |
IDS
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-II |
| RS2520911966 |
GLA
|
Health Risk |
Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520912484 |
LAMP2
|
Health Risk |
Likely pathogenic |
Danon disease, Danon disease |
| RS2520912530 |
LAMP2
|
Health Risk |
Likely pathogenic |
Danon disease, Danon disease |
| RS2520912584 |
GLA
|
Health Risk |
Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520912945 |
GLA
|
Health Risk |
Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520912970 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520913146 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520913256 |
GLA
|
Health Risk |
Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520913284 |
GLA
|
Health Risk |
Pathogenic |
Fabry disease, Fabry disease |
| RS2520913315 |
LAMP2
|
Health Risk |
Pathogenic |
Cardiovascular phenotype, Cardiovascular phenotype |
| RS2520913405 |
GLA
|
Health Risk |
Likely pathogenic |
Fabry disease, Fabry disease |
| RS2520913421 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520913492 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520913626 |
LAMP2
|
Health Risk |
Pathogenic |
Danon disease, Danon disease |
| RS2520914004 |
GLA
|
Health Risk |
Likely pathogenic |
— |
| RS2520914744 |
GLA
|
Health Risk |
Conflicting classifications of pathogenicity |
Fabry disease, Fabry disease |
| RS2520916556 |
CACNA1F
|
Health Risk |
Likely pathogenic |
— |
| RS2520919876 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520920773 |
SMC1A
|
Health Risk |
Likely pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Developmental and epileptic encephalopathy |
| RS2520926208 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520927640 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520927651 |
SMC1A
|
Health Risk |
Conflicting classifications of pathogenicity |
Congenital muscular hypertrophy-cerebral syndrome, Inborn genetic diseases |
| RS2520927817 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520927898 |
ARR3
|
Health Risk |
Likely pathogenic |
ARR3-related disorder, ARR3-related disorder |
| RS2520927961 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520928651 |
SMC1A
|
Health Risk |
Pathogenic |
See cases, See cases |
| RS2520928997 |
SMC1A
|
Health Risk |
Likely pathogenic |
Developmental and epileptic encephalopathy, 85 |
| RS2520929186 |
SMC1A
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520930037 |
SMC1A
|
Health Risk |
Pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520930054 |
SMC1A
|
Health Risk |
Likely pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520930073 |
SMC1A
|
Health Risk |
Likely pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520930904 |
SMC1A
|
Health Risk |
Likely pathogenic |
Congenital muscular hypertrophy-cerebral syndrome, Congenital muscular hypertrophy-cerebral syndrome |
| RS2520934320 |
ARR3
|
Health Risk |
Pathogenic/Likely pathogenic |
Myopia 26, X-linked |
| RS2520938847 |
FRMD7
|
Health Risk |
Likely pathogenic |
— |